Multiple sclerosis: Subtle symptoms and treatment access barriers in Argentina

A woman wakes up with blurred vision. She attributes it to fatigue. Weeks pass. The tingling in her fingers comes and goes. She mentions it to a friend, who suggests stress. By the time she reaches a neurologist, months have elapsed—and by then, the damage is already accumulating in her brain.

This is the story of multiple sclerosis in Argentina, told not in dramatic moments but in the quiet spaces between symptoms that feel like nothing, and a diagnosis that arrives too late. The disease affects thousands of people across the country each year, yet many never see it coming because the early signs are easy to dismiss. Fatigue that doesn't lift with rest. Vision that blurs without warning. Numbness that appears and vanishes. These are the invisible markers of a condition that, once it takes hold, can reshape a life entirely.

Multiple sclerosis is an autoimmune disease—the body's own immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. This interrupts communication between the brain and the rest of the body. Globally, more than 1.8 million people live with the condition, according to the World Health Organization. In Argentina, the incidence ranges from 23.8 to 48.3 cases per 100,000 people. Women are diagnosed far more often than men, a pattern consistent worldwide. The disease typically emerges between ages 20 and 40, during years when people are building careers, starting families, establishing their place in the world.

The problem begins with recognition. Symptoms vary wildly from person to person. Some experience persistent fatigue that no amount of sleep resolves. Others develop blurred or double vision. Tingling, numbness, muscle weakness, balance problems, cognitive difficulties—the list is long and the presentation unpredictable. Neurologist Adriana Carrá, medical director of Esclerosis Múltiple Argentina (EMA), the country's leading patient advocacy organization, explains that the disease "can present in very different ways, with symptoms that appear and disappear or vary in intensity." This variability is precisely what makes early detection so difficult. Initial signs get confused with everyday stress, fatigue from work, or minor neurological quirks. By the time someone connects the dots and seeks help, weeks or months may have passed. And in multiple sclerosis, time matters enormously.

Early treatment with disease-modifying therapies can prevent irreversible neurological damage. María Cecilia Pita, a medical specialist at Roche, notes that current treatments are more targeted and monitoring strategies more sophisticated than ever before, allowing doctors to reduce disease activity and improve quality of life. But this only works if treatment begins soon after diagnosis. When diagnosis is delayed or treatment is postponed, the risk of disease progression increases sharply. Carrá warns that interruptions or delays in accessing treatment carry serious clinical consequences: "When those treatments are administered late, there is a risk of disease reactivation and the appearance of new neurological lesions."

Yet in Argentina, getting that early diagnosis and starting treatment promptly is not straightforward. The EMA has documented persistent barriers: administrative delays, arbitrary changes in insurance coverage, treatment interruptions. Paula Barberá, a lawyer representing the organization, describes a troubling reality: "The judicialization of healthcare access has become routine for many people with multiple sclerosis." Patients and families find themselves navigating bureaucracy instead of focusing on their health. They wait for authorizations. They appeal denials. Some resort to legal action just to access the medications they need.

The psychological toll is substantial. Johana Bauer, a psychologist at EMA, observes that sustained uncertainty generates constant stress. "Many people live in fear of a new relapse while waiting for authorization or medication delivery." Josefina Sorribas, a social worker and EMA coordinator, describes the cascading effects: people abandon work, hobbies, and social activities because they cannot be certain their treatment will continue. Entire families are worn down by the uncertainty and exhaustion of fighting the system. The disease itself demands a profound reorganization of daily life. When patients must also spend enormous energy fighting for coverage and filing legal claims, the emotional impact multiplies.

The path forward, according to EMA and medical experts, requires strengthening diagnostic pathways so people can reach specialists quickly, ensuring continuous access to treatment without bureaucratic obstacles, and recognizing that care extends beyond medication. Rehabilitation, occupational therapy, speech therapy, mental health support, and social accompaniment are all essential. The difference between preserving function and facing progressive disability often comes down to whether a person can access these services without delay. On World Multiple Sclerosis Day, as the organization marks the occasion, the call is clear: make the invisible visible, streamline the systems that diagnose and treat this disease, and ensure that early detection leads to early treatment—not to years of waiting.